- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
One For Choosing Wisely in Breast Cancer
A study presented at the San Antonio Breast Cancer Symposium showed that Herceptin may not complement chemotherapy in breast tumors with a high level of immune infiltration.
HER2-positive breast cancers with a high level of immune cell infiltration might not benefit from the addition of trastuzumab (Herceptin) to chemotherapy, a trial analysis suggested.
The 10% of patients with stromal tumor-infiltrating lymphocyte-predominant breast cancer in the Alliance N9831 trial showed similar recurrence-free survival whether they received chemotherapy alone or with trastuzumab (10-year rate 90.9% versus 80.0%, P = .21), Edith A. Perez, MD, of the Mayo Clinic in Jacksonville, Florida, and colleagues found.
The rest showed, as expected, significantly better recurrence-free survival with addition of trastuzumab (10-year rate 79.6% vs 64.3%, hazard ratio .49, P = .0003), they reported at the San Antonio Breast Cancer Symposium.
Link to the complete report: http://bit.ly/1GjDd6y
Source: Medpage Today
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
